Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 7541-7550 Newer>

The Motley Fool June 15, 2011 Selena Maranjian	Make Money in Biotech the Easy Way There's no need to guess which biotech company will perform best with the SPDR S&P Biotech ETF.
The Motley Fool June 15, 2011 Seth Jayson	Are Cornerstone Therapeutics' Numbers Better Than They Look? With segments moving opposite directions for the periods we're considering, the inventory picture is unclear.
The Motley Fool June 14, 2011 Brian Orelli	Going for Seconds in the Hepatitis C Space Fresh from the Food and Drug Administration's approval of its hepatitis C drug, Incivek, Vertex has licensed a pair of hepatitis C compounds from privately held Alios BioPharma.
The Motley Fool June 14, 2011 Selena Maranjian	Make Money in Health Care the Easy Way There's no need to guess which health-care company will perform best when you invest in the Vanguard Health Care ETF.
The Motley Fool June 14, 2011 Cindy Johnson	Simcere Pharmaceutical Shares Plunged: What You Need to Know Simcere Pharmaceutical Group dropped 10% in intraday trading today as investors continued to doubt the financial health of U.S.-listed Chinese companies.
The Motley Fool June 14, 2011 Frank Vinluan	GSK Epilepsy Drug Approved by FDA GlaxoSmithKline and drug partner Valeant Pharmaceuticals have received U.S. Food and Drug Administration approval on a new epilepsy drug, but it must be classified as a controlled substance.
The Motley Fool June 10, 2011 Brian Orelli	Great Data! Now Lets See More Than 12 Patients Micromet's blinatumomab looks good in a phase 2 trial.
Chemistry World June 10, 2011 Hepeng Jia	Traditional Chinese medicines hampered by EU regulations The European Commission stipulated that traditional Chinese medicines must be registered, before the end of April 2011, prior to being sold in the European Union. But with this deadline passed, very few TCMs have been successfully registered.
The Motley Fool June 10, 2011 Brian Orelli	Abbott Picks Pumps Over Pills Treat Parkinson's disease, medical-device style.
The Motley Fool June 10, 2011 Matt Koppenheffer	Could Teva Pharmaceutical Score You 100% Returns? Is it high time to add Teva's stock to your portfolio?
<Older 7541-7550 Newer> Return to current articles.